A provider-focused briefing on the Catapres discontinuation and Clonidine availability in 2026, including prescribing guidance, alternatives, and patient tools.
If your patients are reporting difficulty finding Catapres, this provider briefing covers the current state of Clonidine availability, the history behind the brand discontinuation, prescribing implications, and tools to help your patients access their medication.
Brand-name Catapres (Clonidine Hydrochloride tablets, manufactured by Boehringer Ingelheim) was permanently discontinued in 2022. This followed a voluntary recall of certain lots in October 2021 due to stability testing concerns. Boehringer Ingelheim subsequently decided not to resume production.
Key point for prescribers: Prescriptions written for "Catapres" may create confusion at the pharmacy level. Update all active prescriptions and templates to generic Clonidine Hydrochloride to ensure seamless dispensing.
The most immediate action item is ensuring your EMR templates and active prescriptions specify Clonidine Hydrochloride rather than Catapres. This prevents:
When prescribing Clonidine, consider the full range of available formulations based on patient needs:
When transitioning patients between formulations or to alternative medications, remember that abrupt Clonidine discontinuation poses a real clinical risk. Rebound hypertension can occur within 18-72 hours of sudden cessation, presenting with:
Always taper Clonidine gradually over 2-4 days when discontinuing. If a patient is on concurrent beta-blocker therapy, discontinue the beta-blocker first (several days before beginning Clonidine taper) to reduce rebound risk.
Generic Clonidine is one of the most affordable antihypertensive medications available:
For patients struggling with cost, savings programs and coupons can help. The Boehringer Ingelheim Cares Foundation Patient Assistance Program may cover eligible patients who need other BI medications, though generic Clonidine's low cost makes PAPs rarely necessary.
Medfinder helps patients locate pharmacies with Clonidine in stock. Consider directing patients to medfinder.com/providers as a resource when they report difficulty finding their medication. It shows real-time pharmacy availability by location.
Direct patients to these evidence-based resources:
When Clonidine is unavailable or contraindicated:
See the patient-facing version: Alternatives to Catapres If You Can't Fill Your Prescription.
The Clonidine market is mature and well-supplied at the generic level. We do not anticipate widespread shortage risks for IR tablets. However, providers should:
The Catapres brand discontinuation was an orderly transition with no patient safety implications, given the robust generic Clonidine supply. The primary action items for providers are straightforward: update prescriptions to generic Clonidine, counsel patients on the brand change, and use tools like Medfinder to help patients locate pharmacies with stock.
For a patient-facing version of this update, see Catapres Shortage Update: What Patients Need to Know in 2026. For guidance on helping patients find medication and manage costs, see How to Help Your Patients Find Catapres in Stock: A Provider's Guide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
